Bugelski PJ - Search Results

1

Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.

Bugelski PJ, Volk A, Walker MR, Krayer JH, Martin P, Descotes J. Bugelski PJ, et al. Int J Toxicol. 2010 Sep-Oct;29(5):435-66. doi: 10.1177/1091581810374654. Int J Toxicol. 2010. PMID: 20884856 Review.

2

Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice.

Rafferty P, Egenolf D, Brosnan K, Makropoulos D, Jordan J, Meshaw K, Walker M, Volk A, Bugelski PJ. Rafferty P, et al. Among authors: bugelski pj. J Immunotoxicol. 2012 Jan-Mar;9(1):43-55. doi: 10.3109/1547691X.2011.614646. J Immunotoxicol. 2012. PMID: 22299716

3

Development of a murine model of lymph node metastases suitable for immunotoxicity studies.

Egenolf DD, Rafferty P, Brosnan K, Walker M, Jordan J, Makropoulos D, Kavalkovich K, Watson S, Johns L, Volk A, Bugelski PJ. Egenolf DD, et al. Among authors: bugelski pj. J Pharmacol Toxicol Methods. 2011 May-Jun;63(3):236-49. doi: 10.1016/j.vascn.2010.12.001. Epub 2010 Dec 13. J Pharmacol Toxicol Methods. 2011. PMID: 21156211

4

Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Bugelski PJ, Martin PL. Bugelski PJ, et al. Br J Pharmacol. 2012 Jun;166(3):823-46. doi: 10.1111/j.1476-5381.2011.01811.x. Br J Pharmacol. 2012. PMID: 22168282 Free PMC article. Review.

5

Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Martin PL, Bugelski PJ. Martin PL, et al. Among authors: bugelski pj. Br J Pharmacol. 2012 Jun;166(3):806-22. doi: 10.1111/j.1476-5381.2011.01812.x. Br J Pharmacol. 2012. PMID: 22168335 Free PMC article. Review.

6

Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.

Walker MR, Makropoulos DA, Achuthanandam R, Van Arsdell S, Bugelski PJ. Walker MR, et al. Among authors: bugelski pj. Int Immunopharmacol. 2011 Nov;11(11):1697-705. doi: 10.1016/j.intimp.2011.06.001. Epub 2011 Jun 29. Int Immunopharmacol. 2011. PMID: 21689786

7

Is murine gammaherpesvirus-68 (MHV-68) a suitable immunotoxicological model for examining immunomodulatory drug-associated viral recrudescence?

Aligo J, Walker M, Bugelski P, Weinstock D. Aligo J, et al. J Immunotoxicol. 2015 Jan-Mar;12(1):1-15. doi: 10.3109/1547691X.2014.882996. Epub 2014 Feb 10. J Immunotoxicol. 2015. PMID: 24512328 Review.

8

Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome.

Walker M, Makropoulos D, Achuthanandam R, Bugelski PJ. Walker M, et al. Among authors: bugelski pj. Curr Opin Drug Discov Devel. 2010 Jan;13(1):124-35. Curr Opin Drug Discov Devel. 2010. PMID: 20047153 Review.

9

Effects of CNTO 530, an erythropoietin mimetic-IgG4 fusion protein, on embryofetal development in rats and rabbits.

Martin PL, Sachs C, Hoberman A, Jiao Q, Bugelski PJ. Martin PL, et al. Among authors: bugelski pj. Birth Defects Res B Dev Reprod Toxicol. 2010 Apr;89(2):87-96. doi: 10.1002/bdrb.20227. Birth Defects Res B Dev Reprod Toxicol. 2010. PMID: 20077575

10

Pharmacodynamics of recombinant human erythropoietin in murine bone marrow.

Bugelski PJ, Nesspor T, Volk A, O'Brien J, Makropoulos D, Shamberger K, Fisher PW, James I, Graden D, Capocasale RJ. Bugelski PJ, et al. Pharm Res. 2008 Feb;25(2):369-78. doi: 10.1007/s11095-007-9372-7. Epub 2007 Jul 4. Pharm Res. 2008. PMID: 17609863

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

119 results

Search Page